Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 3Cognitive Dysfunction 2Tobacco Use Disorder 1Rectal Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Lung Neoplasms 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Radiotherapy 83Temozolomide 78Filgrastim 34Carboplatin 33Vincristine 29Etoposide 26Cyclophosphamide 25Carmustine 25Irinotecan 23Chemotherapy, Adjuvant 23Cisplatin 21Peripheral Blood Stem Cell Transplantation 20Thiotepa 14Lomustine 14Granulocyte Colony-Stimulating Factor 13Surgical Procedures, Operative 12Procarbazine 12Bevacizumab 11Thalidomide 10O(6)-benzylguanine 10Drug Therapy 10etoposide phosphate 9Methotrexate 9Magnetic Resonance Spectroscopy 9Gene Expression Profiling 9Radiation 8Paclitaxel 8sargramostim 7Ifosfamide 7Everolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Central Nervous System Neoplasms × Memantine × Clear all
NCT04217694 2024-11-21

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Mayo Clinic

Phase EARLY_PHASE1 Completed
18 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡